4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.
“[…] It is our ambition to create a fruitful and long-term partnership for our two countries and patients worldwide”, said Dali Zhang, Vice-President of QMBRI.
“We are very pleased to build this partnership with QMBRI’s team. […]”, said Revital Rattenbach, Chairwoman of 4P-Pharma and 4Moving Biotech. “We strongly believe that our combining work will definitely benefit to Chinese, European and worldwide patients.”
“[…] I am especially happy of QMBRI and 4P-Pharma’s partnership”, said Mr. Daowen Du, European director of ICCIC-Gung Ho. “The possibility to provide a quick access of repositioning drugs, whose benefit/risk ratio has been positively proved, to the largest number of people is particularly important for China. We welcome very strongly 4P-Pharma’s expertise to guarantee Chinese drug candidates’ arrival in Europe.”
Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021.
4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion.
Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships.
4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.
“OA-BIO Eurostars grant represents a unique opportunity to bring together some of the most renowned European teams in the field of OA biomarkers […]”, said Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of the INSERM UMR-S938 research.
“OA-BIO […] will advance our understanding on OA biomarkers across the species that typically suffer from OA, like horses and dogs […]”, added Prof. Marianna Tryfonidou, Professor of Regenerative Orthopedics at Faculty of Veterinary Medicine of Utrecht University.
“[…] OA-BIO has a large potential to promote the understanding of the disease and to make a step towards urgently needed therapies”, completed Prof. Felix Eckstein, CEO/CMO of Chondrometrics.
“The OA-BIO consortium breakthrough lies in correlating OA imaging biomarkers with OA molecular ones, […] , as well as to follow how the innovative 4P004 treatment will efficiently interfere with the progression of the OA disease. […]”, concluded Prof. Mauro Alini, Vice-Director of ARI.
4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.
“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks. […]”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma.
“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004. […]”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
4P-Pharma joins forces with Qingdao Marine Biomedical Research Institute for translation research in China and Europe
4P-Pharma and Qingdao Marine Biomedical Research Institute (QMBRI) have decided to combine their expertise to jointly develop their first-in-class drug candidates in China and Europe through the signature of a Memorandum of Understanding (MoU) to deal with their respective molecules.
Read the full press release:
EN: 20210916_PR_MOU_QMBRI_EN
FR: 20210916_PR_MOU_QMBRI_FR
Press contact 4P-Pharma
Roselina Lam, Business Development and Licensing Manager
E-mail: roselina@4p-pharma.com
4Moving Biotech at EULAR 2021
Pr. Francis Berenbaum, 4Moving Biotech’s CEO and CMO, Head of Rheumatology department at Saint-Antoine Hospital (AP-HP), will present a poster entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (# POS0373) on our recent results on 4P004 during the European congress of rheumatology (EULAR) 2021 virtual congress that will take place on June 2-5, 2021.
For further information, please click on the following link : https://congress.eular.org/index.cfm
4P-Pharma at BIO Digital 2021
4P-Pharma will attend the upcoming BIO International Convention held virtually as BIO Digital, on June 10-11 & 14-18, 2021, as part of the Business France virtual French pavilion.
Contact Roselina Lam, our Business Development and Licensing Manager, via the partnering platform or by e-mail, to learn more about us and discuss future partnerships.
She is looking forward to meet you there!
For further information: https://www.bio.org/events/bio-digital
The OA-BIO European Consortium, led by 4Moving Biotech, awarded a Eurostars grant to develop 4P004 through a biomarkers-driven approach
4Moving Biotech (France), Utrecht University (The Netherlands), Chondrometrics GmbH (Germany) and AO Research Institute Davos (Switzerland) have received a EUREKA-Eurostars grant award to finance its €4,2M project (OA-BIO) to complete early clinical development (Phase I) of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD), and to identify and validate OA imaging and liquid biopsy biomarkers.
Read the full press release:
EN: 20210520_PR_4Mov_Eurostars_vEN
FR: 20210520_PR_4Mov_Eurostars_vFR
Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com
4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients
4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.
Read the full press release:
EN: 20210429_PR_4Mov_Closing_vEN
FR: 20210429_PR_4Mov_Financement_FR
Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com